Sharon di Stefano

About the Author Sharon di Stefano

Sharon di Stefano has spent 20 years as an analyst, beginning her career at Smith Barney, Harris Upham & Co. specializing in medical devices, pharmaceuticals, healthcare information technology, and biopharmacology. Ms. di Stefano had also served as Senior Venture Officer for the Edison Innovation Fund, implemented through the New Jersey Economic Development Authority that provided funding for early-stage life sciences companies. Industry experience includes laboratory research for Johns Hopkins Hospital and the Department of Defense. Ms. di Stefano received a Masters of Science degree, in Business, from Johns Hopkins University in 1986, and a Bachelor of Arts from the University of Delaware in 1984 with a minor in biology.

ContraVir Pharmaceuticals Inc (CTRV): Promising New NUC Drug May Eradicate Hepatitis

Sex, one of the most gratifying acts known to humans, can be lethal. A danger exists to thwart this – hepatitis B virus …

Rexahn Pharmaceuticals, Inc. (RNN) From A Bullish Perspective

When a tumor-targeted therapy company advances in clinical trials, pay attention. Rexahn Pharmaceuticals (NYSEMKT:RNN) should be closely watched.

Rexahn Pharmaceuticals, Inc.’s (RNN) Human Data Confirms Anti-Cancer Advantage

New results shown at last week’s European Cancer Congress supported evidence that RX-3117 and Supinoxin, developed by Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), work well …

Pluristem Therapeutics Inc.’s PLX Cells Get Green Light For Fast Track Clinical Trials In Europe And Japan

Quick commercialization of drugs in clinical trials has long been held as a fantasy for makers of pharmaceuticals and biologics. With recent news, …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts